img

Global CINV Existing and Pipeline Drugs Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global CINV Existing and Pipeline Drugs Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Nausea and vomiting are the two most common side effects associated with cancer chemotherapy, and are referred to as chemotherapy induced nausea and vomiting (CINV).
CINV Existing and Pipeline Drugs report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global CINV Existing and Pipeline Drugs market is projected to reach US$ 1954.9 million in 2034, increasing from US$ 1518.2 million in 2022, with the CAGR of 3.2% during the period of 2024 to 2034. Demand from Hospitals and Specialty Clinics are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for CINV Existing and Pipeline Drugs industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, CINV Existing and Pipeline Drugs key manufacturers include GlaxoSmithKline, Helsinn, Heron Therapeutics, Merck and Tesaro, etc. GlaxoSmithKline, Helsinn, Heron Therapeutics are top 3 players and held % sales share in total in 2022.
CINV Existing and Pipeline Drugs can be divided into Aloxi, Zofran Generic, Kytril Generic and Emend, etc. Aloxi is the mainstream product in the market, accounting for % sales share globally in 2022.
CINV Existing and Pipeline Drugs is widely used in various fields, such as Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics and Hospital Pharmacies, etc. Hospitals provides greatest supports to the CINV Existing and Pipeline Drugs industry development. In 2022, global % sales of CINV Existing and Pipeline Drugs went into Hospitals filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global CINV Existing and Pipeline Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


GlaxoSmithKline
Helsinn
Heron Therapeutics
Merck
Tesaro
Segment by Type
Aloxi
Zofran Generic
Kytril Generic
Emend
Akynzeo
SUSTOL
Rolapitant

Segment by Application


Hospitals
Specialty Clinics
Diagnostic Centers Therapeutics
Hospital Pharmacies
Drugstores

Segment by Region


North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the CINV Existing and Pipeline Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of CINV Existing and Pipeline Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the CINV Existing and Pipeline Drugs industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of CINV Existing and Pipeline Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, CINV Existing and Pipeline Drugs introduction, etc. CINV Existing and Pipeline Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of CINV Existing and Pipeline Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.

Table of Content

1 CINV Existing and Pipeline Drugs Market Overview
1.1 CINV Existing and Pipeline Drugs Product Overview
1.2 CINV Existing and Pipeline Drugs Market Segment by Type
1.2.1 Aloxi
1.2.2 Zofran Generic
1.2.3 Kytril Generic
1.2.4 Emend
1.2.5 Akynzeo
1.2.6 SUSTOL
1.2.7 Rolapitant
1.3 Global CINV Existing and Pipeline Drugs Market Size by Type
1.3.1 Global CINV Existing and Pipeline Drugs Market Size Overview by Type (2024-2034)
1.3.2 Global CINV Existing and Pipeline Drugs Historic Market Size Review by Type (2024-2024)
1.3.3 Global CINV Existing and Pipeline Drugs Forecasted Market Size by Type (2024-2034)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America CINV Existing and Pipeline Drugs Sales Breakdown by Type (2024-2024)
1.4.2 Europe CINV Existing and Pipeline Drugs Sales Breakdown by Type (2024-2024)
1.4.3 Asia-Pacific CINV Existing and Pipeline Drugs Sales Breakdown by Type (2024-2024)
1.4.4 Latin America CINV Existing and Pipeline Drugs Sales Breakdown by Type (2024-2024)
1.4.5 Middle East and Africa CINV Existing and Pipeline Drugs Sales Breakdown by Type (2024-2024)
2 Global CINV Existing and Pipeline Drugs Market Competition by Company
2.1 Global Top Players by CINV Existing and Pipeline Drugs Sales (2024-2024)
2.2 Global Top Players by CINV Existing and Pipeline Drugs Revenue (2024-2024)
2.3 Global Top Players by CINV Existing and Pipeline Drugs Price (2024-2024)
2.4 Global Top Manufacturers CINV Existing and Pipeline Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 CINV Existing and Pipeline Drugs Market Competitive Situation and Trends
2.5.1 CINV Existing and Pipeline Drugs Market Concentration Rate (2024-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by CINV Existing and Pipeline Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in CINV Existing and Pipeline Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into CINV Existing and Pipeline Drugs Market
2.8 Key Manufacturers CINV Existing and Pipeline Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 CINV Existing and Pipeline Drugs Status and Outlook by Region
3.1 Global CINV Existing and Pipeline Drugs Market Size and CAGR by Region: 2024 VS 2022 VS 2034
3.2 Global CINV Existing and Pipeline Drugs Historic Market Size by Region
3.2.1 Global CINV Existing and Pipeline Drugs Sales in Volume by Region (2024-2024)
3.2.2 Global CINV Existing and Pipeline Drugs Sales in Value by Region (2024-2024)
3.2.3 Global CINV Existing and Pipeline Drugs Sales (Volume & Value) Price and Gross Margin (2024-2024)
3.3 Global CINV Existing and Pipeline Drugs Forecasted Market Size by Region
3.3.1 Global CINV Existing and Pipeline Drugs Sales in Volume by Region (2024-2034)
3.3.2 Global CINV Existing and Pipeline Drugs Sales in Value by Region (2024-2034)
3.3.3 Global CINV Existing and Pipeline Drugs Sales (Volume & Value), Price and Gross Margin (2024-2034)
4 Global CINV Existing and Pipeline Drugs by Application
4.1 CINV Existing and Pipeline Drugs Market Segment by Application
4.1.1 Hospitals
4.1.2 Specialty Clinics
4.1.3 Diagnostic Centers Therapeutics
4.1.4 Hospital Pharmacies
4.1.5 Drugstores
4.2 Global CINV Existing and Pipeline Drugs Market Size by Application
4.2.1 Global CINV Existing and Pipeline Drugs Market Size Overview by Application (2024-2034)
4.2.2 Global CINV Existing and Pipeline Drugs Historic Market Size Review by Application (2024-2024)
4.2.3 Global CINV Existing and Pipeline Drugs Forecasted Market Size by Application (2024-2034)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America CINV Existing and Pipeline Drugs Sales Breakdown by Application (2024-2024)
4.3.2 Europe CINV Existing and Pipeline Drugs Sales Breakdown by Application (2024-2024)
4.3.3 Asia-Pacific CINV Existing and Pipeline Drugs Sales Breakdown by Application (2024-2024)
4.3.4 Latin America CINV Existing and Pipeline Drugs Sales Breakdown by Application (2024-2024)
4.3.5 Middle East and Africa CINV Existing and Pipeline Drugs Sales Breakdown by Application (2024-2024)
5 North America CINV Existing and Pipeline Drugs by Country
5.1 North America CINV Existing and Pipeline Drugs Historic Market Size by Country
5.1.1 North America CINV Existing and Pipeline Drugs Market Size Growth Rate (CAGR) by Country: 2024 VS 2022 VS 2034
5.1.2 North America CINV Existing and Pipeline Drugs Sales in Volume by Country (2024-2024)
5.1.3 North America CINV Existing and Pipeline Drugs Sales in Value by Country (2024-2024)
5.2 North America CINV Existing and Pipeline Drugs Forecasted Market Size by Country
5.2.1 North America CINV Existing and Pipeline Drugs Sales in Volume by Country (2024-2034)
5.2.2 North America CINV Existing and Pipeline Drugs Sales in Value by Country (2024-2034)
6 Europe CINV Existing and Pipeline Drugs by Country
6.1 Europe CINV Existing and Pipeline Drugs Historic Market Size by Country
6.1.1 Europe CINV Existing and Pipeline Drugs Market Size Growth Rate (CAGR) by Country: 2024 VS 2022 VS 2034
6.1.2 Europe CINV Existing and Pipeline Drugs Sales in Volume by Country (2024-2024)
6.1.3 Europe CINV Existing and Pipeline Drugs Sales in Value by Country (2024-2024)
6.2 Europe CINV Existing and Pipeline Drugs Forecasted Market Size by Country
6.2.1 Europe CINV Existing and Pipeline Drugs Sales in Volume by Country (2024-2034)
6.2.2 Europe CINV Existing and Pipeline Drugs Sales in Value by Country (2024-2034)
7 Asia-Pacific CINV Existing and Pipeline Drugs by Region
7.1 Asia-Pacific CINV Existing and Pipeline Drugs Historic Market Size by Region
7.1.1 Asia-Pacific CINV Existing and Pipeline Drugs Market Size Growth Rate (CAGR) by Region: 2024 VS 2022 VS 2034
7.1.2 Asia-Pacific CINV Existing and Pipeline Drugs Sales in Volume by Region (2024-2024)
7.1.3 Asia-Pacific CINV Existing and Pipeline Drugs Sales in Value by Region (2024-2024)
7.2 Asia-Pacific CINV Existing and Pipeline Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific CINV Existing and Pipeline Drugs Sales in Volume by Region (2024-2034)
7.2.2 Asia-Pacific CINV Existing and Pipeline Drugs Sales in Value by Region (2024-2034)
8 Latin America CINV Existing and Pipeline Drugs by Country
8.1 Latin America CINV Existing and Pipeline Drugs Historic Market Size by Country
8.1.1 Latin America CINV Existing and Pipeline Drugs Market Size Growth Rate (CAGR) by Country: 2024 VS 2022 VS 2034
8.1.2 Latin America CINV Existing and Pipeline Drugs Sales in Volume by Country (2024-2024)
8.1.3 Latin America CINV Existing and Pipeline Drugs Sales in Value by Country (2024-2024)
8.2 Latin America CINV Existing and Pipeline Drugs Forecasted Market Size by Country
8.2.1 Latin America CINV Existing and Pipeline Drugs Sales in Volume by Country (2024-2034)
8.2.2 Latin America CINV Existing and Pipeline Drugs Sales in Value by Country (2024-2034)
9 Middle East and Africa CINV Existing and Pipeline Drugs by Country
9.1 Middle East and Africa CINV Existing and Pipeline Drugs Historic Market Size by Country
9.1.1 Middle East and Africa CINV Existing and Pipeline Drugs Market Size Growth Rate (CAGR) by Country: 2024 VS 2022 VS 2034
9.1.2 Middle East and Africa CINV Existing and Pipeline Drugs Sales in Volume by Country (2024-2024)
9.1.3 Middle East and Africa CINV Existing and Pipeline Drugs Sales in Value by Country (2024-2024)
9.2 Middle East and Africa CINV Existing and Pipeline Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa CINV Existing and Pipeline Drugs Sales in Volume by Country (2024-2034)
9.2.2 Middle East and Africa CINV Existing and Pipeline Drugs Sales in Value by Country (2024-2034)
10 Company Profiles
10.1 GlaxoSmithKline
10.1.1 GlaxoSmithKline Company Information
10.1.2 GlaxoSmithKline Introduction and Business Overview
10.1.3 GlaxoSmithKline CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2024-2024)
10.1.4 GlaxoSmithKline CINV Existing and Pipeline Drugs Products Offered
10.1.5 GlaxoSmithKline Recent Development
10.2 Helsinn
10.2.1 Helsinn Company Information
10.2.2 Helsinn Introduction and Business Overview
10.2.3 Helsinn CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2024-2024)
10.2.4 Helsinn CINV Existing and Pipeline Drugs Products Offered
10.2.5 Helsinn Recent Development
10.3 Heron Therapeutics
10.3.1 Heron Therapeutics Company Information
10.3.2 Heron Therapeutics Introduction and Business Overview
10.3.3 Heron Therapeutics CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2024-2024)
10.3.4 Heron Therapeutics CINV Existing and Pipeline Drugs Products Offered
10.3.5 Heron Therapeutics Recent Development
10.4 Merck
10.4.1 Merck Company Information
10.4.2 Merck Introduction and Business Overview
10.4.3 Merck CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2024-2024)
10.4.4 Merck CINV Existing and Pipeline Drugs Products Offered
10.4.5 Merck Recent Development
10.5 Tesaro
10.5.1 Tesaro Company Information
10.5.2 Tesaro Introduction and Business Overview
10.5.3 Tesaro CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2024-2024)
10.5.4 Tesaro CINV Existing and Pipeline Drugs Products Offered
10.5.5 Tesaro Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 CINV Existing and Pipeline Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 CINV Existing and Pipeline Drugs Industrial Chain Analysis
11.4 CINV Existing and Pipeline Drugs Market Dynamics
11.4.1 CINV Existing and Pipeline Drugs Industry Trends
11.4.2 CINV Existing and Pipeline Drugs Market Drivers
11.4.3 CINV Existing and Pipeline Drugs Market Challenges
11.4.4 CINV Existing and Pipeline Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 CINV Existing and Pipeline Drugs Distributors
12.3 CINV Existing and Pipeline Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of Aloxi
Table 2. Major Company of Zofran Generic
Table 3. Major Company of Kytril Generic
Table 4. Major Company of Emend
Table 5. Major Company of Akynzeo
Table 6. Major Company of SUSTOL
Table 7. Major Company of Rolapitant
Table 8. Global CINV Existing and Pipeline Drugs Sales by Type 2024 VS 2022 VS 2034 (US$ Million)
Table 9. Global CINV Existing and Pipeline Drugs Sales by Type (2024-2024) & (Kg)
Table 10. Global CINV Existing and Pipeline Drugs Sales Market Share in Volume by Type (2024-2024)
Table 11. Global CINV Existing and Pipeline Drugs Sales by Type (2024-2024) & (US& Million)
Table 12. Global CINV Existing and Pipeline Drugs Market Share in Value by Type (2024-2024)
Table 13. Global CINV Existing and Pipeline Drugs Price by Type (2024-2024) & (USD/Kg)
Table 14. Global CINV Existing and Pipeline Drugs Sales by Type (2024-2034) & (Kg)
Table 15. Global CINV Existing and Pipeline Drugs Sales Market Share in Volume by Type (2024-2034)
Table 16. Global CINV Existing and Pipeline Drugs Sales by Type (2024-2034) & (US$ Million)
Table 17. Global CINV Existing and Pipeline Drugs Sales Market Share in Value by Type (2024-2034)
Table 18. Global CINV Existing and Pipeline Drugs Price by Type (2024-2034) & (USD/Kg)
Table 19. North America CINV Existing and Pipeline Drugs Sales by Type (2024-2024) & (Kg)
Table 20. North America CINV Existing and Pipeline Drugs Sales by Type (2024-2024) & (US$ Million)
Table 21. Europe CINV Existing and Pipeline Drugs Sales (Kg) by Type (2024-2024)
Table 22. Europe CINV Existing and Pipeline Drugs Sales by Type (2024-2024) & (US$ Million)
Table 23. Asia-Pacific CINV Existing and Pipeline Drugs Sales (Kg) by Type (2024-2024)
Table 24. Asia-Pacific CINV Existing and Pipeline Drugs Sales by Type (2024-2024) & (US$ Million)
Table 25. Latin America CINV Existing and Pipeline Drugs Sales (Kg) by Type (2024-2024)
Table 26. Latin America CINV Existing and Pipeline Drugs Sales by Type (2024-2024) & (US$ Million)
Table 27. Middle East and Africa CINV Existing and Pipeline Drugs Sales (Kg) by Type (2024-2024)
Table 28. Middle East and Africa CINV Existing and Pipeline Drugs Sales by Type (2024-2024) & (US$ Million)
Table 29. Global CINV Existing and Pipeline Drugs Sales by Company (2024-2024) & (Kg)
Table 30. Global CINV Existing and Pipeline Drugs Sales Share by Company (2024-2024)
Table 31. Global CINV Existing and Pipeline Drugs Revenue by Company (2024-2024) & (US$ Million)
Table 32. Global CINV Existing and Pipeline Drugs Revenue Share by Company (2024-2024)
Table 33. Global Market CINV Existing and Pipeline Drugs Price by Company (2024-2024) & (USD/Kg)
Table 34. Global CINV Existing and Pipeline Drugs Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 35. Global CINV Existing and Pipeline Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 36. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in CINV Existing and Pipeline Drugs as of 2022)
Table 37. Date of Key Manufacturers Enter into CINV Existing and Pipeline Drugs Market
Table 38. Key Manufacturers CINV Existing and Pipeline Drugs Product Type
Table 39. Mergers & Acquisitions, Expansion Plans
Table 40. Global CINV Existing and Pipeline Drugs Market Size Comparison by Region (US$ Million): 2024 VS 2022 VS 2034
Table 41. Global CINV Existing and Pipeline Drugs Sales by Region (2024-2024) & (Kg)
Table 42. Global CINV Existing and Pipeline Drugs Sales Market Share in Volume by Region (2024-2024)
Table 43. Global CINV Existing and Pipeline Drugs Sales by Region (2024-2024) & (US$ Million)
Table 44. Global CINV Existing and Pipeline Drugs Sales Market Share in Value by Region (2024-2024)
Table 45. Global CINV Existing and Pipeline Drugs Sales (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2024-2024)
Table 46. Global CINV Existing and Pipeline Drugs Sales by Region (2024-2034) & (Kg)
Table 47. Global CINV Existing and Pipeline Drugs Sales Market Share in Volume by Region (2024-2034)
Table 48. Global CINV Existing and Pipeline Drugs Sales by Region (2024-2034) & (US$ Million)
Table 49. Global CINV Existing and Pipeline Drugs Sales Market Share in Value by Region (2024-2034)
Table 50. Global CINV Existing and Pipeline Drugs Sales (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2024-2034)
Table 51. Global CINV Existing and Pipeline Drugs Sales by Application: 2024 VS 2022 VS 2034 (US$ Million)
Table 52. Global CINV Existing and Pipeline Drugs Sales by Application (2024-2024) & (Kg)
Table 53. Global CINV Existing and Pipeline Drugs Sales Market Share in Volume by Application (2024-2024)
Table 54. Global CINV Existing and Pipeline Drugs Sales by Application (2024-2024) & (US$ Million)
Table 55. Global CINV Existing and Pipeline Drugs Sales Market Share in Value by Application (2024-2024)
Table 56. Global CINV Existing and Pipeline Drugs Price by Application (2024-2024) & (USD/Kg)
Table 57. Global CINV Existing and Pipeline Drugs Sales by Application (2024-2034) & (Kg)
Table 58. Global CINV Existing and Pipeline Drugs Sales Market Share in Volume by Application (2024-2034)
Table 59. Global CINV Existing and Pipeline Drugs Sales by Application (2024-2034) & (US$ Million)
Table 60. Global CINV Existing and Pipeline Drugs Sales Market Share in Value by Application (2024-2034)
Table 61. Global CINV Existing and Pipeline Drugs Price by Application (2024-2034) & (USD/Kg)
Table 62. North America CINV Existing and Pipeline Drugs Sales by Application (2024-2024) (Kg)
Table 63. North America CINV Existing and Pipeline Drugs Sales by Application (2024-2024) & (US$ Million)
Table 64. Europe CINV Existing and Pipeline Drugs Sales by Application (2024-2024) (Kg)
Table 65. Europe CINV Existing and Pipeline Drugs Sales by Application (2024-2024) & (US$ Million)
Table 66. Asia-Pacific CINV Existing and Pipeline Drugs Sales by Application (2024-2024) (Kg)
Table 67. Asia-Pacific CINV Existing and Pipeline Drugs Sales by Application (2024-2024) & (US$ Million)
Table 68. Latin America CINV Existing and Pipeline Drugs Sales by Application (2024-2024) (Kg)
Table 69. Latin America CINV Existing and Pipeline Drugs Sales by Application (2024-2024) & (US$ Million)
Table 70. Middle East and Africa CINV Existing and Pipeline Drugs Sales by Application (2024-2024) (Kg)
Table 71. Middle East and Africa CINV Existing and Pipeline Drugs Sales by Application (2024-2024) & (US$ Million)
Table 72. North America CINV Existing and Pipeline Drugs Sales by Country (2024-2024) & (Kg)
Table 73. North America CINV Existing and Pipeline Drugs Sales Market Share in Volume by Country (2024-2024)
Table 74. North America CINV Existing and Pipeline Drugs Sales by Country (2024-2024) & (US$ Million)
Table 75. North America CINV Existing and Pipeline Drugs Sales Market Share in Value by Country (2024-2024)
Table 76. North America CINV Existing and Pipeline Drugs Sales by Country (2024-2034) & (Kg)
Table 77. North America CINV Existing and Pipeline Drugs Sales Market Share in Volume by Country (2024-2034)
Table 78. North America CINV Existing and Pipeline Drugs Sales by Country (2024-2034) & (US$ Million)
Table 79. North America CINV Existing and Pipeline Drugs Sales Market Share in Value by Country (2024-2034)
Table 80. Europe CINV Existing and Pipeline Drugs Sales by Country (2024-2024) & (Kg)
Table 81. Europe CINV Existing and Pipeline Drugs Sales Market Share in Volume by Country (2024-2024)
Table 82. Europe CINV Existing and Pipeline Drugs Sales by Country (2024-2024) & (US$ Million)
Table 83. Europe CINV Existing and Pipeline Drugs Sales Market Share in Value by Country (2024-2024)
Table 84. Europe CINV Existing and Pipeline Drugs Sales by Country (2024-2034) & (Kg)
Table 85. Europe CINV Existing and Pipeline Drugs Sales Market Share in Volume by Country (2024-2034)
Table 86. Europe CINV Existing and Pipeline Drugs Sales by Country (2024-2034) & (US$ Million)
Table 87. Europe CINV Existing and Pipeline Drugs Sales Market Share in Value by Country (2024-2034)
Table 88. Asia-Pacific CINV Existing and Pipeline Drugs Sales by Region (2024-2024) & (Kg)
Table 89. Asia-Pacific CINV Existing and Pipeline Drugs Sales Market Share in Volume by Region (2024-2024)
Table 90. Asia-Pacific CINV Existing and Pipeline Drugs Sales by Region (2024-2024) & (US$ Million)
Table 91. Asia-Pacific CINV Existing and Pipeline Drugs Sales Market Share in Value by Region (2024-2024)
Table 92. Asia-Pacific CINV Existing and Pipeline Drugs Sales by Region (2024-2034) & (Kg)
Table 93. Asia-Pacific CINV Existing and Pipeline Drugs Sales Market Share in Volume by Region (2024-2034)
Table 94. Asia-Pacific CINV Existing and Pipeline Drugs Sales by Region (2024-2034) & (US$ Million)
Table 95. Asia-Pacific CINV Existing and Pipeline Drugs Sales Market Share in Value by Region (2024-2034)
Table 96. Latin America CINV Existing and Pipeline Drugs Sales by Country (2024-2024) & (Kg)
Table 97. Latin America CINV Existing and Pipeline Drugs Sales Market Share in Volume by Country (2024-2024)
Table 98. Latin America CINV Existing and Pipeline Drugs Sales by Country (2024-2024) & (US$ Million)
Table 99. Latin America CINV Existing and Pipeline Drugs Sales Market Share in Value by Country (2024-2024)
Table 100. Latin America CINV Existing and Pipeline Drugs Sales by Country (2024-2034) & (Kg)
Table 101. Latin America CINV Existing and Pipeline Drugs Sales Market Share in Volume by Country (2024-2034)
Table 102. Latin America CINV Existing and Pipeline Drugs Sales by Country (2024-2034) & (US$ Million)
Table 103. Latin America CINV Existing and Pipeline Drugs Sales Market Share in Value by Country (2024-2034)
Table 104. Middle East and Africa CINV Existing and Pipeline Drugs Sales by Country (2024-2024) & (Kg)
Table 105. Middle East and Africa CINV Existing and Pipeline Drugs Sales Market Share in Volume by Country (2024-2024)
Table 106. Middle East and Africa CINV Existing and Pipeline Drugs Sales by Country (2024-2024) & (US$ Million)
Table 107. Middle East and Africa CINV Existing and Pipeline Drugs Sales Market Share in Value by Country (2024-2024)
Table 108. Middle East and Africa CINV Existing and Pipeline Drugs Sales by Country (2024-2034) & (Kg)
Table 109. Middle East and Africa CINV Existing and Pipeline Drugs Sales Market Share in Volume by Country (2024-2034)
Table 110. Middle East and Africa CINV Existing and Pipeline Drugs Sales by Country (2024-2034) & (US$ Million)
Table 111. Middle East and Africa CINV Existing and Pipeline Drugs Sales Market Share in Value by Country (2024-2034)
Table 112. GlaxoSmithKline Company Information
Table 113. GlaxoSmithKline Introduction and Business Overview
Table 114. GlaxoSmithKline CINV Existing and Pipeline Drugs Sales (Kg), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2024-2024)
Table 115. GlaxoSmithKline CINV Existing and Pipeline Drugs Product
Table 116. GlaxoSmithKline Recent Development
Table 117. Helsinn Company Information
Table 118. Helsinn Introduction and Business Overview
Table 119. Helsinn CINV Existing and Pipeline Drugs Sales (Kg), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2024-2024)
Table 120. Helsinn CINV Existing and Pipeline Drugs Product
Table 121. Helsinn Recent Development
Table 122. Heron Therapeutics Company Information
Table 123. Heron Therapeutics Introduction and Business Overview
Table 124. Heron Therapeutics CINV Existing and Pipeline Drugs Sales (Kg), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2024-2024)
Table 125. Heron Therapeutics CINV Existing and Pipeline Drugs Product
Table 126. Heron Therapeutics Recent Development
Table 127. Merck Company Information
Table 128. Merck Introduction and Business Overview
Table 129. Merck CINV Existing and Pipeline Drugs Sales (Kg), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2024-2024)
Table 130. Merck CINV Existing and Pipeline Drugs Product
Table 131. Merck Recent Development
Table 132. Tesaro Company Information
Table 133. Tesaro Introduction and Business Overview
Table 134. Tesaro CINV Existing and Pipeline Drugs Sales (Kg), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2024-2024)
Table 135. Tesaro CINV Existing and Pipeline Drugs Product
Table 136. Tesaro Recent Development
Table 137. Key Raw Materials Lists
Table 138. Raw Materials Key Suppliers Lists
Table 139. CINV Existing and Pipeline Drugs Market Trends
Table 140. CINV Existing and Pipeline Drugs Market Drivers
Table 141. CINV Existing and Pipeline Drugs Market Challenges
Table 142. CINV Existing and Pipeline Drugs Market Restraints
Table 143. CINV Existing and Pipeline Drugs Distributors List
Table 144. CINV Existing and Pipeline Drugs Downstream Customers
Table 145. Research Programs/Design for This Report
Table 146. Key Data Information from Secondary Sources
Table 147. Key Data Information from Primary Sources
List of Figures
Figure 1. CINV Existing and Pipeline Drugs Product Picture
Figure 2. Global CINV Existing and Pipeline Drugs Market Size, 2024 VS 2022 VS 2034 (US$ Million)
Figure 3. Global CINV Existing and Pipeline Drugs Market Size Status and Outlook (2024-2034) & (US$ Million)
Figure 4. Global CINV Existing and Pipeline Drugs Sales Status and Outlook (2024-2034) & (Kg)
Figure 5. Product Picture of Aloxi
Figure 6. Global Aloxi Sales YoY Growth (2024-2034) & (Kg)
Figure 7. Product Picture of Zofran Generic
Figure 8. Global Zofran Generic Sales YoY Growth (2024-2034) & (Kg)
Figure 9. Product Picture of Kytril Generic
Figure 10. Global Kytril Generic Sales YoY Growth (2024-2034) & (Kg)
Figure 11. Product Picture of Emend
Figure 12. Global Emend Sales YoY Growth (2024-2034) & (Kg)
Figure 13. Product Picture of Akynzeo
Figure 14. Global Akynzeo Sales YoY Growth (2024-2034) & (Kg)
Figure 15. Product Picture of SUSTOL
Figure 16. Global SUSTOL Sales YoY Growth (2024-2034) & (Kg)
Figure 17. Product Picture of Rolapitant
Figure 18. Global Rolapitant Sales YoY Growth (2024-2034) & (Kg)
Figure 19. Global CINV Existing and Pipeline Drugs Sales by Type (2024-2034) & (US$ Million)
Figure 20. Global CINV Existing and Pipeline Drugs Sales Market Share by Type in 2022 & 2034
Figure 21. North America CINV Existing and Pipeline Drugs Sales Market Share in Volume by Type in 2022
Figure 22. North America CINV Existing and Pipeline Drugs Sales Market Share in Value by Type in 2022
Figure 23. Europe CINV Existing and Pipeline Drugs Sales Market Share in Volume by Type in 2022
Figure 24. Europe CINV Existing and Pipeline Drugs Sales Market Share in Value by Type in 2022
Figure 25. Asia-Pacific CINV Existing and Pipeline Drugs Sales Market Share in Volume by Type in 2022
Figure 26. Asia-Pacific CINV Existing and Pipeline Drugs Sales Market Share in Value by Type in 2022
Figure 27. Latin America CINV Existing and Pipeline Drugs Sales Market Share in Volume by Type in 2022
Figure 28. Latin America CINV Existing and Pipeline Drugs Sales Market Share in Value by Type in 2022
Figure 29. Middle East and Africa CINV Existing and Pipeline Drugs Sales Market Share in Volume by Type in 2022
Figure 30. Middle East and Africa CINV Existing and Pipeline Drugs Sales Market Share in Value by Type in 2022
Figure 31. The 5 and 10 Largest Manufacturers in the World: Market Share by CINV Existing and Pipeline Drugs Sales in 2022
Figure 32. The 5 and 10 Largest Manufacturers in the World: Market Share by CINV Existing and Pipeline Drugs Revenue in 2022
Figure 33. CINV Existing and Pipeline Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2024 VS 2022
Figure 34. Product Picture of Hospitals
Figure 35. Global Hospitals Sales YoY Growth (2024-2034) & (Kg)
Figure 36. Product Picture of Specialty Clinics
Figure 37. Global Specialty Clinics Sales YoY Growth (2024-2034) & (Kg)
Figure 38. Product Picture of Diagnostic Centers Therapeutics
Figure 39. Global Diagnostic Centers Therapeutics Sales YoY Growth (2024-2034) & (Kg)
Figure 40. Product Picture of Hospital Pharmacies
Figure 41. Global Hospital Pharmacies Sales YoY Growth (2024-2034) & (Kg)
Figure 42. Product Picture of Drugstores
Figure 43. Global Drugstores Sales YoY Growth (2024-2034) & (Kg)
Figure 44. Global CINV Existing and Pipeline Drugs Sales by Application (2024-2034) & (US$ Million)
Figure 45. Global CINV Existing and Pipeline Drugs Sales Market Share by Application in 2022 & 2034
Figure 46. North America CINV Existing and Pipeline Drugs Sales Market Share in Volume by Application in 2022
Figure 47. North America CINV Existing and Pipeline Drugs Sales Market Share in Value by Application in 2022
Figure 48. Europe CINV Existing and Pipeline Drugs Sales Market Share in Volume by Application in 2022
Figure 49. Europe CINV Existing and Pipeline Drugs Sales Market Share in Value by Application in 2022
Figure 50. Asia-Pacific CINV Existing and Pipeline Drugs Sales Market Share in Volume by Application in 2022
Figure 51. Asia-Pacific CINV Existing and Pipeline Drugs Sales Market Share in Value by Application in 2022
Figure 52. Latin America CINV Existing and Pipeline Drugs Sales Market Share in Volume by Application in 2022
Figure 53. Latin America CINV Existing and Pipeline Drugs Sales Market Share in Value by Application in 2022
Figure 54. Middle East and Africa CINV Existing and Pipeline Drugs Sales Market Share in Value by Application in 2022
Figure 55. Key Raw Materials Price
Figure 56. CINV Existing and Pipeline Drugs Manufacturing Cost Structure
Figure 57. CINV Existing and Pipeline Drugs Industrial Chain Analysis
Figure 58. Channels of Distribution
Figure 59. Distributors Profiles
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries